Forte Biosciences (FBRX) Cash from Financing Activities (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly Cash from Financing Activities of $74000.0 for Q1 2026, up 103.19% year-over-year from $36419.7 in Q1 2025, and up 722.22% quarter-over-quarter from $9000.0 in Q4 2025.
Forte Biosciences (FBRX) Cash from Financing Activities (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Cash from Financing Activities for 11 consecutive years, with $74000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 103.19% year-over-year to $74000.0; the TTM figure through Mar 2026 stood at $71.8 million (up 44.84% YoY), while the FY2025 annual figure was $69.4 million, up 33.75% from the prior year.
- Cash from Financing Activities rose to $74000.0 in Q1 2026 per FBRX's latest filing, from $9000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $70.3 million in Q2 2025 and bottomed at -$2.3 million in Q1 2025.
- Historically, Cash from Financing Activities has averaged $9.0 million across 5 years, with a median of -$2000.0 in 2024.
- On a YoY basis, Cash from Financing Activities climbed as much as 703590.0% in 2025 and fell as far as 28925.0% in 2025.
- Forte Biosciences' Cash from Financing Activities stood at -$55000.0 in 2022, then sank by 36.36% to -$75000.0 in 2023, then surged by 69269.33% to $51.9 million in 2024, then sank by 99.98% to $9000.0 in 2025, then surged by 722.22% to $74000.0 in 2026.
- Business Quant data shows FBRX's Cash from Financing Activities at $74000.0 in Q1 2026, $9000.0 in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - | 161.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 161.95 Mn |
| Jun 30, 2026 | 161.95 Mn |
| Mar 31, 2026 | 74,000.00 |
| Mar 31, 2026 | 74,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Sep 30, 2025 | 1.33 Mn |
| Sep 30, 2025 | 1.33 Mn |
| Jun 30, 2025 | 70.35 Mn |
| Jun 30, 2025 | 70.35 Mn |
| Mar 31, 2025 | -2.32 Mn |
| Mar 31, 2025 | -2.32 Mn |
| Dec 31, 2024 | 51.88 Mn |
| Dec 31, 2024 | 51.88 Mn |
| Sep 30, 2024 | -2,000.00 |
| Sep 30, 2024 | -2,000.00 |
| Jun 30, 2024 | -10,000.00 |
| Jun 30, 2024 | -10,000.00 |
| Mar 31, 2024 | -8,000.00 |
| Mar 31, 2024 | -8,000.00 |